Proactiveinvestors recommends
Additional Information
Market: TSE
Sector: Pharmaceuticals
EPIC: RBM
Response Biomedical Corp
www.responsebio.com

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

Full Response Biomedical Corp profile here
Pdf

Response Biomedical losses narrow as diagnostic tests sales gather pace

12th Mar 2010, 1:58 pm
Response Biomedical losses narrow as diagnostic tests sales gather pace

Response Biomedical Corporation’s (TSX: RBM, OTCBB: RPBIF) revenues in 2009 climbed 69% to approximately $9.95 million as sales of its on-site diagnostic tests gathered momentum. Clinical products revenue for the year ended December 31, 2009 increased 85% to $6.8 million.


Net losses narrowed from US$13.6 million or 10 cents per share in 2008, to US$9.5 million or 4 cents per share in 2009.  At the end of 2009, Response Biomedical had US$7 million in working capital.


"2009 was the strongest revenue year in the history of the Company and we are poised to realize similar growth in 2010," said S. Wayne Kay, Chief Executive officer. "Our success in 2009 was driven in great part by our partners, Roche Diagnostics and 3M Health Care, as they continue to recognize achievements in the U.S. O&D Biotech, our distribution partner in China, was also a strong contributor to our overall growth in clinical products revenue in 2009 and Shionogi continued to show steady expansion in Japan."


Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications.


Roche and 3M Health Care are both distributors for Response Biomedical.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.